3BP-3940, a highly potent FAP-targeting peptide for theranostics - production, validation and first in human experience with Ga-68 and Lu-177

Autor: Greifenstein, Lukas, Gunkel, Annika, Hoehne, Aileen, Osterkamp, Frank, Smerling, Christiane, Landvogt, Christian, Mueller, Corinna, Baum, Richard P.

Publikováno v: In iScience 15 December 2023 26(12)

Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition.

Autor: Zboralski, Dirk¹ (AUTHOR) dirk.zboralski@3b-pharma.com, Osterkamp, Frank¹ (AUTHOR), Christensen, Esben² (AUTHOR), Bredenbeck, Anne¹ (AUTHOR), Schumann, Anne¹ (AUTHOR), Hoehne, Aileen¹ (AUTHOR), Schneider, Eberhard¹ (AUTHOR), Paschke, Matthias¹ (AUTHOR), Ungewiss, Jan¹ (AUTHOR), Haase, Christian¹ (AUTHOR), Robillard, Liliane³ (AUTHOR), Simmons, Andrew D.³ (AUTHOR), Harding, Thomas C.³ (AUTHOR), Nguyen, Minh³ (AUTHOR)

Publikováno v: European Journal of Nuclear Medicine & Molecular Imaging. Jul2023, Vol. 50 Issue 9, p2621-2635. 15p. 2 Color Photographs, 5 Graphs.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Feasibility, Biodistribution and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy (PTRT) of Diverse Adenocarcinomas using ¹⁷⁷Lu-FAP-2286: Firstin- Human Results.

Autor: Baum, Richard P., Schuchardt, Christiane, Singh, Aviral, Chantadisai, Maythinee, Robiller, Franz C., Jingjing Zhang, Mueller, Dirk, Eismant, Alexander, Almaguel, Frankis, Zboralski, Dirk, Osterkamp, Frank, Hoehne, Aileen, Reineke, Ulrich, Smerling, Christiane, Kulkarni, Harshad R.

Publikováno v: Journal of Nuclear Medicine; Dec2021, Vol. 62 Issue 12, Following p1-32, 45p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.